BridgeBio announced that the Palo Alto, Calif.-based biopharmaceutical company signed an exclusive deal with Bristol Myers Squibb to develop and commercialize a potential treatment for cancer.


Fresh off a presentation of positive data showing that the KRASG12C inhibitor adagrasib benefited colorectal and lung cancer patients, Mirati Therapeutics forged an agreement to combine the drug with Sanofi’s company’s SHP2 inhibitor SAR442720 in lung cancer.

California-based biopharmaceutical firm BridgeBio Pharma announced a funding collaboration with Bristol Myers Squibb to evaluate a potential treatment for patients with difficult-to-treat cancers.